YUFLYMA 20 MG / 0.2 ML
ADALIMUMAB : 20 MG / 0.2 ML · DIN 02556596 · CELLTRION INC.
Health Canada status: APPROVED
What is YUFLYMA?
YUFLYMA 20 MG / 0.2 ML contains ADALIMUMAB : 20 MG / 0.2 ML. It is listed in the Health Canada Drug Product Database under DIN 02556596, held by CELLTRION INC., supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as approved, status dated 19-Jun-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02556596 |
|---|---|
| Brand name | YUFLYMA |
| Generic / active ingredient | ADALIMUMAB : 20 MG / 0.2 ML |
| Manufacturer | CELLTRION INC. |
| Strength | 20 MG / 0.2 ML |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Schedule D |
| ATC code | L04AB04 ADALIMUMAB |
| Biosimilar | Yes |
| Health Canada status | APPROVED |
| Status date | 19-Jun-2025 |
What can be used instead?
Other Canadian products sharing ATC code L04AB04 ADALIMUMAB. 34 of 41 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ABRILADA | 20 MG / 0.4 ML | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02511061 |
| ABRILADA | 40 MG / 0.8 ML | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02511045 |
| ABRILADA | 40 MG / 0.8 ML | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02511053 |
| AMGEVITA | 50 MG | SOLUTION | AMGEN CANADA INC | MARKETED | DIN 02459310 |
| AMGEVITA | 50 MG | SOLUTION | AMGEN CANADA INC | MARKETED | DIN 02459302 |
| AMGEVITA | 50 MG | SOLUTION | AMGEN CANADA INC | MARKETED | DIN 02459299 |
| HADLIMA | 40 MG / 0.4 ML | SOLUTION | SAMSUNG BIOEPIS CO., LTD | MARKETED | DIN 02533472 |
| HADLIMA | 40 MG / 0.8 ML | SOLUTION | SAMSUNG BIOEPIS CO., LTD | MARKETED | DIN 02473097 |
| HADLIMA PUSHTOUCH | 40 MG / 0.4 ML | SOLUTION | SAMSUNG BIOEPIS CO., LTD | MARKETED | DIN 02533480 |
| HADLIMA PUSHTOUCH | 40 MG / 0.8 ML | SOLUTION | SAMSUNG BIOEPIS CO., LTD | MARKETED | DIN 02473100 |
Who else supplies ADALIMUMAB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ADALIMUMAB appears in 3291 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.